The only way to improve cancer detection, prevention, and treatment is through research. People participating in research contribute to medical knowledge and have opportunity to receive cutting-edge care.
Nivolumab vs Placebo Combined with Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy for High-risk ER+, HER2-Negative Breast Cancer (CheckMate 7FL)
Clinicaltrials.gov identifier:
NCT04109066
Newly-diagnosed, non-metastatic, ER-positive, HER2-negative breast cancer
Study Contact Information:
For more information about the study, visit:
bmsstudyconnect.com/us/en/clinical-trials/NCT04109066.html
Nivolumab vs Placebo Combined with Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy for High-risk ER+, HER2-Negative Breast Cancer (CheckMate 7FL)
About the Study
The CA209-7FL clinical trial is researching if a study drug combined with pre-surgery chemotherapy, surgery, and post-surgery endocrine therapy could be safe, effective, and improve outcomes for people with ER+, HER-negative breast cancer. This will be compared to a group that receives a in addition to the same pre-surgery chemotherapy, surgery, and post-surgery endocrine therapy standard of care. NOTE: This study is no longer enrolling patients.
For more information about the study, visit: https://www.bmsstudyconnect.com/us/en/clinical-trials/NCT04109066.html
NOTE: This study is no longer enrolling patients.
NOTE: This study is no longer enrolling patients.